Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

Blood (2022) 140 (Supplement 1): 3480–3482.

https://doi.org/10.1182/blood-2022-169102

Published: 2022

Journal Articles

FLT3 ITD AML Outcomes Are Impacted By Exposure to One Cycle of Cytarabine Based Consolidation, Pre- and Post-Transplant TKI Therapy, and Presence of Minimal Residual Disease (MRD) Prior to Allogeneic Blood or Marrow Transplant

Blood (2017) 130 (Supplement 1): 2593.

https://doi.org/10.1182/blood.V130.Suppl_1.2593.2593

Published: 2017

Journal Articles

Aberrant Hedgehog Signaling in Myelodysplastic Syndrome Accelerates Leukemic Transformation Via Smoothened-Dependent and Smoothened-Independent Gli1 Activation

Bonnie W Lau, MD PhD, Kyounghee Huh, MS, Rafael Madero-Marroquin, MD, Federico De Marchi, MD, Yiting Lim, PhD, Francisco Lobo, PhD, Luigi Marchionni, PhD, Peter D. Aplan, MD, William Matsui, MD, Lukasz P. Gondek, MD PhD

Blood (2017) 130 (Supplement 1): 1676.

https://doi.org/10.1182/blood.V130.Suppl_1.1676.1676

Published: 2017

Journal Articles

Protein Synthesis Rates Regulate Tumor-Initiating Potential and Chemoresistance in Multiple Myeloma

Eun-Hee Park, PhD, Mehrnoosh Soori, PhD MSc, Qiuju Wang, MSc, Lukasz P. Gondek, MD PhD, William Matsui, MD, Christian B. Gocke, MD PhD

Blood (2017) 130 (Supplement 1): 4390.

https://doi.org/10.1182/blood.V130.Suppl_1.4390.4390

Published: 2017

Journal Articles

Bone Marrow Niche - Multiple Myeloma Cross-Talk Generates Bortezomib Resistance

Salvador Alonso, MD, William Matsui, MD, Richard J Jones, MD, Gabriel Ghiaur, MD PhD

Blood (2015) 126 (23): 914.

https://doi.org/10.1182/blood.V126.23.914.914

Published: 2015

Journal Articles

Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death

Mark B Meads, PhD, Bin Fang, PhD, Linda Mathews, Jennifer Gemmer, MS, Liang Nong, MD, Ismael Rosado-Lopez, Tuan Nguyen, Jennifer E. Ring, William Matsui, MD, Robert MacLeod, PhD, David T. Weaver, PhD, Jonathan A. Pachter, PhD, Lori A. Hazlehurst, PhD, John M. Koomen, PhD, Kenneth H. Shain, MD PhD

Blood (2015) 126 (23): 3008.

https://doi.org/10.1182/blood.V126.23.3008.3008

Published: 2015

Journal Articles

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Blood (2014) 124 (25): 3817–3827.

https://doi.org/10.1182/blood-2014-07-587477

Published: 2014

Includes: Supplemental data

Journal Articles

Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death

Kenneth H. Shain, MD PhD, Mark B Meads, PhD, Bin Fang, PhD, Linda Mathews, Jennifer Gemmer, Liang Nong, MD, Ismael Rosado-Lopez, BS, Jennifer E. Ring, Robert MacLeod, PhD, Lori Hazlehurst, PhD, Conor Lynch, PhD, Jonathan A. Pachter, PhD, William Matsui, MD, John Koomen, PhD, Tuan Nguyen

Blood (2014) 124 (21): 2081.

https://doi.org/10.1182/blood.V124.21.2081.2081

Published: 2014

Journal Articles

Inhibiting Oncogenic RAS in Multiple Myeloma By Targeting Scaffold-ERK Interactions

Christian B. Gocke, MD PhD, Qiuju Wang, MA, Ross McMillan, Vesselin Penchev, Julien Sage, PhD, Paul A Khavari, MD PhD, William Matsui, MD

Blood (2014) 124 (21): 2089.

https://doi.org/10.1182/blood.V124.21.2089.2089

Published: 2014

Journal Articles

Aberrant Hedgehog Pathway Activity Marks Clinical MDS Progression and Accelerates Leukemic Transformation in Vivo

Lukasz P Gondek, MD PhD, Yiting Lim, PhD, Hideki Makishima, MD PhD, Qiuju Wang, MA, Jaroslaw P. Maciejewski, MD PhD FACP, Peter D Aplan, MD, Amy E. DeZern, MD MHS, William Matsui, MD

Blood (2014) 124 (21): 528.

https://doi.org/10.1182/blood.V124.21.528.528

Published: 2014

Journal Articles

Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells

Toshihiko Tanno, Yiting Lim, Qiuju Wang, Marta Chesi, P. Leif Bergsagel, Geoff Matthews, Ricky W. Johnstone, Nilanjan Ghosh, Ivan Borrello, Carol Ann Huff, William Matsui

Blood (2014) 123 (5): 725–733.

https://doi.org/10.1182/blood-2013-08-524025

Published: 2014

Includes: Supplemental data

Journal Articles

Outcomes Of Allogeneic Blood Or Marrow Transplantation (AlloBMT) In Multiple Myeloma With Post-Transplantation Cyclophosphamide (PTCy)

Nilanjan Ghosh, MD, PhD, Xiaobu Ye, MD, MS, Javier Bolaños-Meade, MD, Ephraim J. Fuchs, Leo Luznik, Jennifer A. Kanakry, Robert A. Brodsky, MD, Mark Levis, MD, PhD, Lode J. Swinnen, Douglas Gladstone, MD, Yvette L. Kasamon, Richard F. Ambinder, Richard J. Jones, William Matsui, MD, Ivan M. Borrello, MD, Carol Ann Huff, M.D.

Blood (2013) 122 (21): 3407.

https://doi.org/10.1182/blood.V122.21.3407.3407

Published: 2013

Journal Articles

Dissecting The Potential Role Of Prevnar As An Anti-Myeloma Vaccine

Kimberly Noonan, PhD, MPH, Lakshmi Rudraraju, MS, Anna Ferguson, RN, Amy Sidorski, NP, Andrea Casildo, BS, Ervin Griffin, Susan Lee, BS, Nilanjan Ghosh, MD, PhD, William Matsui, MD, Carol Huff, M.D., Ivan M. Borrello, MD

Blood (2013) 122 (21): 1980.

https://doi.org/10.1182/blood.V122.21.1980.1980

Published: 2013

Journal Articles

The Telomerase Inhibitor, Imetelstat, Rapidly Reduces Myeloma Cancer Stem Cells (CSCs) in a Phase II Trial

Carol Ann Huff, M.D., Quiju Wang, MS, Ashraf Z. Badros, MD, Richard J. Jones, Anita Reddy, PhD, Kevin Nishimoto, PhD, Monic J. Stuart, MD, MPH, Stephen M Kelsey, MD, William Matsui, MD

Blood (2012) 120 (21): 4898.

https://doi.org/10.1182/blood.V120.21.4898.4898

Published: 2012

Journal Articles

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

Blood (2012) 120 (9): 1877–1887.

https://doi.org/10.1182/blood-2011-12-396853

Published: 2012

Includes: Supplemental data

Journal Articles

The redox-sensitive transcription factor Nrf2 regulates murine hematopoietic stem cell survival independently of ROS levels

Akil A. Merchant, Anju Singh, William Matsui, Shyam Biswal

Blood (2011) 118 (25): 6572–6579.

https://doi.org/10.1182/blood-2011-05-355362

Published: 2011

Includes: Supplemental data

Journal Articles

Targeting Brouton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenström Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment

Blood (2011) 118 (21): 883.

https://doi.org/10.1182/blood.V118.21.883.883

Published: 2011

Journal Articles

The TGF- β Family Member Growth Differentiation Factor 15 (GDF15) Regulates the Self-Renewal of Multiple Myeloma Cancer Stem Cells

Toshihiko Tanno, DVM, PhD, Akil Merchant, MD, Jasmin R. Agarwal, MD, MSc, Qiuju Wang, MA, William Matsui, MD

Blood (2011) 118 (21): 2954.

https://doi.org/10.1182/blood.V118.21.2954.2954

Published: 2011

Journal Articles

Phase I/II Study of Marrow Infiltrating Lymphocytes (MILs) Generates Measurable Myeloma-Specific Immunity in the Autologous Stem Cell Transplant (SCT) Setting

Kimberly Noonan, MPH, Carol A. Huff, MD, Janice M Davis Sproul, MAS, MT(ASCP), SBB, Mario Victor M Lemas, PhD, Lakshmi Rudraraju, MS, Leo Luznik, Jonathan Powell, MD, PhD, Javier Bolaños-Meade, Jeffrey Bitzan, MT, Susan Fiorino, MT(ASCP), William Matsui, MD, Richard J. Jones, MD, Ivan M. Borrello, MD

Blood (2011) 118 (21): 997.

https://doi.org/10.1182/blood.V118.21.997.997

Published: 2011

Journal Articles

Improved Survival and Recovery of Hematopoiesis Following Lethal Radiation by Chloroquine-Mediated Activation of ATM

Yiting Lim, BS, Mohammad Hedayati, PhD, Akil Merchant, MD, Yonggang Zhang, MD, Theodore DeWeese, MD, William Matsui, MD

Blood (2010) 116 (21): 2228.

https://doi.org/10.1182/blood.V116.21.2228.2228

Published: 2010

NARROW

Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

FLT3 ITD AML Outcomes Are Impacted By Exposure to One Cycle of Cytarabine Based Consolidation, Pre- and Post-Transplant TKI Therapy, and Presence of Minimal Residual Disease (MRD) Prior to Allogeneic Blood or Marrow Transplant

Aberrant Hedgehog Signaling in Myelodysplastic Syndrome Accelerates Leukemic Transformation Via Smoothened-Dependent and Smoothened-Independent Gli1 Activation

Protein Synthesis Rates Regulate Tumor-Initiating Potential and Chemoresistance in Multiple Myeloma

Bone Marrow Niche - Multiple Myeloma Cross-Talk Generates Bortezomib Resistance

Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death

Inhibiting Oncogenic RAS in Multiple Myeloma By Targeting Scaffold-ERK Interactions

Aberrant Hedgehog Pathway Activity Marks Clinical MDS Progression and Accelerates Leukemic Transformation in Vivo

Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells

Outcomes Of Allogeneic Blood Or Marrow Transplantation (AlloBMT) In Multiple Myeloma With Post-Transplantation Cyclophosphamide (PTCy)

Dissecting The Potential Role Of Prevnar As An Anti-Myeloma Vaccine

The Telomerase Inhibitor, Imetelstat, Rapidly Reduces Myeloma Cancer Stem Cells (CSCs) in a Phase II Trial

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

The redox-sensitive transcription factor Nrf2 regulates murine hematopoietic stem cell survival independently of ROS levels

Targeting Brouton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenström Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment

The TGF- β Family Member Growth Differentiation Factor 15 (GDF15) Regulates the Self-Renewal of Multiple Myeloma Cancer Stem Cells

Phase I/II Study of Marrow Infiltrating Lymphocytes (MILs) Generates Measurable Myeloma-Specific Immunity in the Autologous Stem Cell Transplant (SCT) Setting

Improved Survival and Recovery of Hematopoiesis Following Lethal Radiation by Chloroquine-Mediated Activation of ATM

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only